ScripWhen clinical trial details are teased but deferred, investors will take a steer from the company management and key opinion leader commentaries. This has the potential for bias. Recent events around
ScripAstraZeneca and Daiichi Sankyo’s HER2-targeting antibody-drug conjugate Enhertu (trastuzumab deruxtecan), used in combination with Roche’s HER2-targeting Perjeta (pertuzumab), has potential to change
ScripAstraZeneca’s Phase III SERENA-6 study of camizestrant could usher in a new treatment paradigm by using biomarker testing to detect emerging resistance in breast cancer and change therapy without wait
ScripGilead Sciences’ TROP2-directed antibody-drug conjugate Trodelvy (sacituzumab govitecan-hziy) has a strong chance of cornering most of the market for first-line advanced or metastatic triple-negative